Registered No. Intervention Vaccine Type Start Year Patient Phase Sponsor Status
NCT00610389 DC loaded with autologous tumor Therapeutic vaccine 2008 Metastatic HCC II Clinica Universidad de Navarra Unknown
NCT01128803 Autologous DCs loaded with AFP peptides Therapeutic vaccine 2009 AFP ≥ 40 ng/ml  I/II Nantes University Hospital Terminated
NCT00669136 AFP + GM-CSF plasmid prime and AFP adenoviral vector boost Therapeutic vaccine 2009 Locoregionally treated HCC I/II Lisa H. Butterfield, Ph.D. Terminated due to poor accrual
NCT01828762 Autologous DCs incubated with irradiated autologous tumor stem cells and suspended in GM-CSF Therapeutic vaccine 2012 Candidates for resection I Cellular Biomedicine Group Ltd. Completed
NCT01522820 DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine Therapeutic vaccine 2012 After resection and TACE I Roswell Park Cancer Institute Not recruiting
NCT01974661 Allogenic DC based therapeutic vaccine Therapeutic vaccine 2013 Not eligible for curative treatment or TACE  I Immunicum AB Recruiting
NCT01923233 ALLOSTIM(TM) in-situ vaccine in combination with RFA Therapeutic vaccine 2013 Refractory HCC I ImmunovativeTherapies, Ltd. withdrawn prior to enrollment
NCT02232490 hepcortespenlisimut-L (V5) Therapeutic vaccine 2015 Advanced HCC III Lisichansk Regional Tuberculosis Dispensary Recruiting
AFP: α-fetoprotein; DC: Dendritic Cell; GM-CSF: Granulocytes Macrophage Colony-Stimulating Factor; HCC: Hepatocellular Carcinoma; TACE: TransarterialChemoembolization; RFA: Radiofrequency Ablation
Table 4: Clinical trials of tumor vaccine on hepatocellular carcinoma.